stockrow
Saturday 7 November 2026
Export GRDX’s income statement to Excel — free account
GridAI Technologies Corp.
GRDX Healthcare Biotechnology
GridAI Technologies Corp.’s revenue for fiscal 2025 (year ended December 2025) was $36,300.00.
- EPS
- −773.9%
- Free cash flow
- −2,641.0%
- Total debt
- −64.0%
Quarter to June 2026, against a year earlier
4.79
0.12
+2.57%
Follow GRDX
Alert me
GridAI Technologies Corp. (GRDX) P/E ratio
GridAI Technologies Corp. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.3× (June 2023) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
Against its own ten years
Low 0.0×
High 0.3×
Ten-year median
0.0×
Current reading's percentile
97
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| VERU Veru Inc. compare | n/m |
| PTHS Pelthos Therapeutics Inc. compare | n/m |
| GRDX GridAI Technologies Corp. | n/m |
| INMB INmune Bio, Inc. compare | n/m |
| NNVC NanoViricides, Inc. compare | n/m |
| PMN Promis Neurosciences compare | n/m |
| EYPT EyePoint, Inc. compare | n/m |
| TVGN Tevogen Inc. compare | n/m |
| LIANY LianBio Sponsored ADR compare | 0.0× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)